Synthesis of 2,4-Diamino-6-[2′-O-(ω -carboxyalkyl)oxydibenz[b,f]azepin-5-yl]-methylpteridines as Potent and Selective Inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium Dihydrofolate Reductase

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2475-2485

  Rosowsky, Andre ^a   Fu, Hongning ^a   Chan, David C M ^a   Queener, Sherry F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 6 [2' O (3 CARBOXYPROPYL)OXYDIBENZ[B,F]AZEPIN 5 YL]METHYLPTERIDINE; 2,4 DIAMINO 6 [2' O (4 CARBOXYBENZYL)OXYDIBENZ[B,F]AZEPIN 5 YL]METHYLPTERIDINE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROFOLIC ACID; N (2,4 DIAMINOPTERIDIN 6 YL)METHYLDIBENZ[B,F]AZEPINE DERIVATIVE; PIRITREXIM; TETRAHYDROFOLIC ACID; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

ANIMALS; AZEPINES; BENZAZEPINES; FOLIC ACID ANTAGONISTS; MODELS, MOLECULAR; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS CARINII; PTERIDINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; WATER;

EID: 2342468066     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030599o     Document Type: Article

References (74)

1. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
2. Menéndez-Arias, L. Targeting. HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 2002, 23, 381-388.
3. (a) Moore, R. D. Cost-effectiveness of combination HIV therapy; 3 years later. Pharmacoeconomics 2000, 17, 325-330.
4. (b) Freedberg, K. A.; Losina, E.; Weinstein, M. C.; Paltiel, A. D.; Cohen, C. J.; Seage, G. R.; Craven, D. E.; Zhang, H.; Kimmel, A. D.; Goldie, S. J. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 2001, 344, 824-831.
5. (a) Kaplan, J. E.; Hu, D. J.; Holmes, K. K.; Jaffe, H. W.; Masur, H.; De Cock, K. M. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am. J. Trop. Med. Hyg. 1996, 55, 1-11.
6. (b) Moore, R. D.; Chaisson, R. E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 1996, 124, 633-642.
7. (a) Piot, P. Global AIDS epidemic: time to turn the tide. Science 2000, 288, 2176-2178.
8. (b) Parker, R. The global HIV/AIDS pandemic, structural inequalities, and the politics of international health. Am. J. Public Health 2002, 92, 343-346.
9. Kovacs, J. A.; Gill, V. J.; Meshnick, S.; Masur, H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. J. Am. Med. Assoc. 2001, 286, 2450-2460.
10. Wong, S. Y.; Remington, J. S. Biology of Toxoplasma gondii. AIDS 1993, 7, 299-316.
11. (a) Belanger, F.; Derouin, F.; Grangeot-Keros, L.; Meyer, L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin. Infect. Dis. 1999, 28, 575-581.
12. (b) Neuenburg, J. K.; Brodt, H. R.; Herndier, B. G.; Bickel, M.; Bacchetti, P.; Price, R. W.; Grant, R. M.; Schlote, W. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2002, 31, 171-177.
13. (c) Nath, A.; Sinai, A. P. Cerebral toxoplasmosis. Curr. Treat. Options Neurol. 2003, 5, 3-12.
14. (a) Horsburgh, C. R., Jr.; Gettings, J.; Alexander, L. N.; Lennox, J. L. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus. Clin. Infect. Dis. 2001, 33, 1938-1943.
15. (b) Pozniak, A. Mycobacterial diseases and HIV. J. HIV Ther. 2002, 7, 13-16.
16. (b) von Reyn, C. F.; Arbeit, R. D.; Horsburgh, C. R.; Ristola, M. A.; Waddell, R. D.; Tvaroha, S. M.; Samore, M.; Hirschhorn, L. R.; Lumio, J.; Lein, A. D.; Grove, M. R.; Tosteson, A. N. Sources of disseminated Mycobacterium avium infection in AIDS. J. Infect. 2002, 44, 166-170.
17. Guerrant, R. L. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis. 1997, 3, 51-57.
18. (b) Clark D. P. New insights into human cryptoporidiosis. Clin Microbiol. Rev. 1999, 12, 554-563.
19. (c) Oldfield, E. C., III. Evaluation of chronic diarrhea in patients with human immunodeficiency virus infection. Rev. Gastroenterol. Disord. 2002, 2, 176-188.
20. (a) Rosowsky, A.; Forsch, R. A.; Queener, S. F. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(ω -carboxyalkyloxy)benzyl]pyrimidines: Marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J. Med. Chem. 2002, 45, 233-242.
21. (b) Rosowsky, A.; Forsch, R. A.; Queener, S. F. Further studies on 2,4-diamino-5′(2′, 5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reduces from three major opportunistic pathogens of AIDS. J. Med Chem. 2003, 46, 1726-1736; see this paper for a list of papers from this laboratory from 1993 to 2002.
22. (a) Gangjee, A.; Dubash, N. P.; Queener, S. F. The synthesis of new diaminofuro[2,3-d]pyrimidines with 5-biphenyl, phenoxyphenyl and tricyclic substitutions as dihydrofolate reductase inhibitors. J. Heterocycl. Chem. 2000, 37, 935-942; see also many other papers from this group prior to 2000.
23. (b) Gangjee, A.; Adair, O.; Queener, S. F. Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Bioorg. Med. Chem. 2001, 9, 2929-2935.
24. (c) Gangjee, A.; Zheng, Y.; McGuire, J. J.; Kisliuk, R. L. Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deazaantifolates. J. Med. Chem. 2002, 45, 5173-5181.
25. (a) Piper, J. R.; Johnson, C. A.; Krauth, C. A.; Carter, R. L.; Hosmer, C. A.; Queener, S. F.; Borotz, S. E.; Pfefferkorn, E. R. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. J. Med. Chem. 1996, 39, 1271-1280.
26. (b) Suling, W. J.; Seitz, L. E.; Pathak, V.; Westbrook, L.; Barrow, E. W.; Zywnovan Ginkel, S.; Reynolds, R. C.; Piper, J. R.; Barrow, W. R. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase. Antimicrob. Agents Chemother. 2000, 44, 2784-2793.
27. (a) Stevens, M. F. G.; Phillip, K. S.; Rathbone, D. L.; O'Shea, D. M.; Queener, S. F.; Schwalbe, C. H.; Lambert P. A. Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocytis carinii dihydrofolate reductase. J. Med. Chem. 1997, 40, 1886-1893.
28. (b) Cody, V.; Chan, D.; Galitsky, N.; Rak, D.; Luft, J. R.; Pangborn, W. ; Queener, S. F.; Laughton, C. A.; Stevens, M. F. G. Structural studies on bioactive compounds. 30. Crystal structure and molecular studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate. Biochemistry 2000, 39, 3556-3564.
29. Robson, C.; Meek, M. A.; Grunwaldt, J.-D.; Lambert, P. A.; Queener, S. F.; Schmidt, D.; Griffin, R. J. Nonclassical 2-diamino-5-aryl-6-ethylpyrimidine antifolates: Activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. J. Med. Chem. 1997, 40, 3040-3048.
30. For selected clinical examples, see: (a) Fischl, M. A.; Dickinson, G. M. ; La Voie, L. Safety and efficacy of sulfamethoxazole and trimethoprim prophylaxis for Pneumocystis carinii pneumonia in AIDS. J. Am. Med. Assoc. 1988, 259, 1185-1189.
31. (b) Medina, I.; Mills, H, Leuong, G.; Hopewell, P. C.; Lee, B.; Modin, G.; Benowitz, N.; Wofsy, C. B. Oral therapy for Pheumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N. Engl. J. Med. 1990, 323, 776-782.
32. (c) Podzamczer, D.; Salazar, A.; Jimenez, J.; Consiglio, E.; Santin, M.; Casanova, A.; Rufi, G.; Gudiol, G. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann. Intern. Med. 1995, 122, 755-761.
33. (d) Fraser, I.; Macintosh, I.; Wilkins, E. G. Prophylactic effect of co-trimoxazole for Mycobacterium avium complex infection: a previously unreported benefit. Clin. Infect. Dis. 1994, 19, 211.
34. Roudier, C.; Caumes, E.; Rogeaux, O.; Bricaire, F.; Gentilini, M. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch. Dermatol. 1994, 130, 1383-1386.
35. Ma, L.; Borio, L.; Masur, H.; Kovacs, J. A. Pheumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 1999, 180, 1969-1978.
36. (a) Sattler, F. R.; Frame, P.; Davis, R.; Nichols, L.; Shelton, B.; Akil, B.; Baughman, R.; Hughlett, C.; Weiss, W.; Boylen, C. T.; van der Horst, C.; Black, J.; Powderly, W.; Steigbigel, R. T.; Leedom, J. M.; Masur, H.; Feinberg, J.; Benoit, S.; Eyster, E.; Gocke, D.; Beck. K.; Lederman, M.; Phari, J.; Reichman, R.; Sacks, H. S.; Soiero, R. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect. Dis. 1994, 170, 165-172.
37. (b) Fulton, B.; Wagstaff, A. J.; McTavish, D. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs 1995 49, 563-576.
38. Falloon, J.; Allegra, C. J.; Kovacs, J.; O'Neill, D.; Ogata-Arakaki, D.; Feuerstein, I.; Polis, M.; Davey, R.; Lane, H. C.; LaFon, S.; Rogers, M.; Zunich, K.; Turlo, J.; Tuazon, C.; Parenti, D.; Simon, G.; Masur, H. Piritrexim with leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Clin. Res. 1990, 38, 361A.
39. Kovacs, J. A.; Allegra, C. J.; Beaver, J.; Boarman, D.; Lewis, M.; Parrillo, J. E.; Chabner, B.; Masur, H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: Potential for screening therapeutic agents. J. Infect. Dis. 1989, 160, 312-320.
40. Rosowsky, A.; Cody, V.; Galitsky, N.; Fu, H.; Papoulis, A. T.; Queener, S. F. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain. J. Med. Chem. 1999, 42, 4853-4860.
41. Cody, V.; Galitsky, N.; Luft, J. R.; Pangborn, W.; Rosowsky, A.; Queener, S. F. Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH. Acta Crystallogr. 2002, D58, 946-954.
42. Rosowsky, A.; Fu, H.; Queener, S. F. Synthesis of new 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4-diaminoquinazolines with bulky dibenz[b,f]azepine and dibenzo[a,d] cycloheptene substituents at the 6-positiion as inhibitors of dihydrofolate reductases from Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium. J. Heterocycl Chem. 2000, 37, 921-926.
43. Haque, K. H.; Hardie, K. M.; Proctor, G. R. Novel aromatic systems. Part IX. Synthesis and substitutions of dibenzo[b,f]-azepin-2-one. J. Chem. Soc., Perkin Trans. 1 1972, 539-542.
44. Chang, V. H. T. Synthesis of 2-hydrocycarbamazepine. A metabolite of carbam-azepine. J. Heterocycl. Chem. 1983, 20, 237-238.
45. (a) Stadler, P. A.; Frey, A. J.; Troxler, R.; Hofmann, A. Selective reduction and oxidation reactions of lysergic acid derivates. Helv. Chim. Acta 1964, 47, 756-769.
46. (b) Saa, J. M.; Capo, M.; Marti, C.; Garcia-Raso, A. Oxidative degradation of 6-hydroxy-1,2,3,4-tetrahydroisoquinolines and 7-hydroxy-2-benazepines. A novel route to heterocyclic quinones. J. Org. Chem. 1990, 55, 288-292.
47. (c) Islam, L.; Skibo, E. B.; Dorr, R. T.; Alberts, D. S. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles. New reductive alkylating DNA cleaving agents. J. Med. Chem. 1991, 34, 2954-2961.
48. (d) Giethlen, B.; Schaus, J. M. Oxidation of indolines with Fremy's salt: A mechanistic proposal. Tetrahedron Lett. 1997, 38, 3483-3486.
49. (d) Kraus, G. A.; Selvakumar, N. A novel Fremy's salt-mediated oxidation and rearrangement of anilines into amino orthodiketones. Applications to the synthesis of pyrrolobenzodiazepines. Tetrahedron Lett. 1999, 40, 2039-2040.
50. Taylor, E. C.; Portnoy, R. C.; Hochstetler, D. C.; Kobayashi, T. Pteridines. XXXVIII. Synthesis of some 2,4-diamino-6-substituted methylpteridines. A new route to pteroic acid. J. Org. Chem. 1975, 40, 2347-2351.
51. Rosowsky, A.; Forsch, R. A.; Queener, S. F.; Bertino, J. R. Synthesis of 2,4-diaminopteridines with bulky lipophilic groups at the 6-position as inhibitors of Pneumocystis carinii, Toxoplasma gondii, and mammalian dihydrofolate reductase. Pteridines 1997, 8, 173-187.
52. Kuyper, L. F.; Roth, B.; Baccanari, D. P.; Ferone, R.; Beddell, C. R.; Champness, J. N.; Stammers, D. K.; Dann, J. G.; Norrington, F. E.; Baker, D. J. ; Goodford. P. J. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues. J. Med. Chem. 1985, 28, 303-311.
53. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
54. 3H]-uracil incorporation assay method should have been 16b instead of 17c.
55. Then, R. L.; Hartman, P. G.; Kompis, I.; Stephan-Güldner, M.; Stöckel, K. Epiroprim. Drugs Future 1994, 19, 446-449.
56. Gangjee, A.; Vasudevan, A.; Queener, S. F.; Kisliuk, R. L. 2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases. J. Med. Chem. 1996, 39, 1438-1446.
57. 50 values and the accompanying discussion, the potency and selectivity of 6 for Pc versus human and for Pc versus rat DHFR are very similar.
58. Structural studies on rat DHFR by crystallography are in progress in the laboratory of Dr. Vivian Cody, Hauptman-Woodward Medical Research Institute, Buffalo, NY.
59. For computational studies on the set of pyrido[2,3-d]pyrimidine analogues synthesized by Suling and co-workers,13b as well as our lead compound 6, see: Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase, see J. Med. Chem. 2002, 45, 41-53. For a more recent modeling study in which several of these structures were docked into a homology model of Ma DHFR derived from a published 3D structure for Mycobacterium tuberculosis DHFR, see: Kharkar, P. S.; Kulkarni, V. M. A proposed model of Mycobacterium avium complex dihydrofolate reductase and its utility for drug design. Org. Biomol. Chem. 2003, 1, 1315-1322.
60. For computational studies on the set of pyrido[2,3-d]pyrimidine analogues synthesized by Suling and co-workers,13b as well as our lead compound 6, see: Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase, see J. Med. Chem. 2002, 45, 41-53. For a more recent modeling study in which several of these structures were docked into a homology model of Ma DHFR derived from a published 3D structure for Mycobacterium tuberculosis DHFR, see: Kharkar, P. S.; Kulkarni, V. M. A proposed model of Mycobacterium avium complex dihydrofolate reductase and its utility for drug design. Org. Biomol. Chem. 2003, 1, 1315-1322.
61. (a) Dhople, A. L. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int. J. Antimicrob. Agents 1999, 12, 319-323.
62. (b) Dhople, A. L. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J. Antimicrob. Chemother. 2001, 47, 93-96.
63. Tripos, Inc., St. Louis, MO.
64. In the discussion of the interactions of 10 with Pc and human DHFR, the ring to which the 2′-substituent is attached is called the A-ring, the azepine ring is called the B-ring, and the third ring in the tricyclic system is called the C-ring.
65. Andrews, P.; Dooley, M. Role of molecular recognition in drug design. In: Textbook of Drug Design and Discovery, 3rd ed.; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Taylor and Francis Publishers: London, UK, 2000; pp 35-53.
66. (a) Cody, V.; Rosowsky, A. Crystal structure determination of human DHFR binary complexes with TMP and modeling studies of TMP analogues. AACR Proc. 2002, 43, 1021.
67. (b) Personal communication from Dr. Vivian Cody.
68. Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham, T. E., III; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER 7; University of California, San Francisco, 2002.
69. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074.
70. Cornell, W.; Cieplak, P.; Bayly, C.; Gould, I.; Merz, K.; Ferguson, D.; Spellmeyer, D.; Fox, T.; Caldwell, J.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
71. Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC Model: I. Methodol. J. Comput. Chem. 2000, 21, 132-146.
72. Stewart, J. J. P. Rossi, I.; Hu, W. P.; Lynch, G. C.; Liu, Y. P.; Chuang, Y. Y.; Li, J.; Cramer, C. J.; Fast, P. L.; Truhlar, D. G. MOPAC version 5. 09mn; University of Minnesota, Minneapolis, 1999.
73. Cody, V.; Galitsky, N.; Luft, J. R.; Pangborn, W.; Rosowsky, A.; Blakley, R. L. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes with reduced nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry 1997, 36, 13897-13903.
74. Ryckaert, J.; Ciccoti, G.; Berendsen, H. Numerical integration of the Cartesian equations of motion for a system of constraints. J. Comput. Phys. 1977, 23, 327-341.